Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer
Robert Pirker
ROBERT PIRKER , Medical University of Vienna
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080316_robert_pirker.mp3]
